EP Wealth Advisors LLC boosted its position in Hologic (NASDAQ:HOLX) by 6.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 209,167 shares of the medical equipment provider’s stock after buying an additional 12,132 shares during the quarter. EP Wealth Advisors LLC owned approximately 0.08% of Hologic worth $8,942,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Zeke Capital Advisors LLC purchased a new stake in Hologic in the fourth quarter worth approximately $357,000. LPL Financial LLC boosted its stake in Hologic by 18.9% in the fourth quarter. LPL Financial LLC now owns 47,281 shares of the medical equipment provider’s stock worth $2,021,000 after buying an additional 7,509 shares in the last quarter. Flinton Capital Management LLC boosted its stake in Hologic by 9.2% in the fourth quarter. Flinton Capital Management LLC now owns 18,904 shares of the medical equipment provider’s stock worth $808,000 after buying an additional 1,598 shares in the last quarter. Cornerstone Capital Management Holdings LLC. boosted its stake in Hologic by 8.7% in the fourth quarter. Cornerstone Capital Management Holdings LLC. now owns 51,831 shares of the medical equipment provider’s stock worth $2,214,000 after buying an additional 4,167 shares in the last quarter. Finally, OLD Mission Capital LLC purchased a new stake in Hologic in the fourth quarter worth approximately $387,000. 97.56% of the stock is owned by institutional investors and hedge funds.
NASDAQ:HOLX opened at $36.43 on Friday. The company has a quick ratio of 0.98, a current ratio of 1.25 and a debt-to-equity ratio of 0.87. The company has a market cap of $10,306.24, a PE ratio of 17.95, a P/E/G ratio of 1.68 and a beta of 0.85. Hologic has a fifty-two week low of $35.33 and a fifty-two week high of $46.80.
Hologic (NASDAQ:HOLX) last announced its earnings results on Thursday, February 8th. The medical equipment provider reported $0.55 EPS for the quarter, beating analysts’ consensus estimates of $0.50 by $0.05. The company had revenue of $791.10 million during the quarter, compared to the consensus estimate of $785.80 million. Hologic had a return on equity of 20.07% and a net margin of 34.53%. The firm’s revenue for the quarter was up 7.7% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.52 earnings per share. sell-side analysts anticipate that Hologic will post 2.25 earnings per share for the current year.
Several analysts have issued reports on the company. Needham & Company LLC reaffirmed a “buy” rating and issued a $50.00 target price (up previously from $48.00) on shares of Hologic in a research note on Tuesday, January 9th. Deutsche Bank lowered Hologic from a “buy” rating to a “hold” rating and set a $49.00 price objective for the company. in a research note on Friday, January 19th. BidaskClub lowered Hologic from a “hold” rating to a “sell” rating in a research note on Saturday, January 13th. Cowen raised Hologic to a “buy” rating and set a $52.00 price objective for the company in a research note on Wednesday, December 20th. Finally, Bank of America raised Hologic from a “neutral” rating to a “buy” rating and set a $50.00 price objective for the company in a research note on Thursday, January 4th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and nine have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $47.21.
In related news, SVP Allison P. Bebo sold 7,000 shares of the company’s stock in a transaction that occurred on Friday, March 16th. The stock was sold at an average price of $38.75, for a total transaction of $271,250.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Namal Nawana bought 6,600 shares of the firm’s stock in a transaction that occurred on Tuesday, February 13th. The shares were acquired at an average price of $37.88 per share, with a total value of $250,008.00. Following the acquisition, the director now owns 6,954 shares of the company’s stock, valued at $263,417.52. The disclosure for this purchase can be found here. 0.79% of the stock is owned by corporate insiders.
TRADEMARK VIOLATION WARNING: This piece of content was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark law. The correct version of this piece of content can be read at https://www.dispatchtribunal.com/2018/04/07/hologic-inc-holx-shares-bought-by-ep-wealth-advisors-llc.html.
Hologic Company Profile
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.